← back to search

Jianji Pan

Fujian Medical University · CN
🔎 Find collaborators in Otorhinolaryngology · Surgery →
Search 5.9M scientists by topic, h-index, country & funding — free.
Area of research
Otorhinolaryngology · Surgery
Research interest
Research interests include Head and Neck Cancer Studies, Head and Neck Surgical Oncology, Esophageal Cancer Research and Treatment, and Spectroscopy Techniques in Biomedical and Chemical Research.
h-index
48
citations
8,064
works
313
NIH funding
primary concept
Medicine
email

Recent publications

Deep learning-based quantification of tumor-infiltrating lymphocytes as a prognostic indicator in nasopharyngeal carcinoma: multicohort findings
ESMO Open 2025cited by 7position: middledoi
Identifying adverse nodal features associated with poor prognosis in stage IB nasopharyngeal carcinoma patients based on the 9th AJCC/UICC staging system: Implications for treatment intensification
Radiotherapy and Oncology 2025cited by 2position: middledoi
Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma
JAMA 2023cited by 222position: middledoi
Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)
Cancer Cell 2023cited by 208position: middledoi
Methylglyoxal from gut microbes boosts radiosensitivity and radioimmunotherapy in rectal cancer by triggering endoplasmic reticulum stress and cGAS-STING activation
Journal for ImmunoTherapy of Cancer 2023cited by 42position: middledoi
STING Agonist‐Loaded Nanoparticles Promotes Positive Regulation of Type I Interferon‐Dependent Radioimmunotherapy in Rectal Cancer
Advanced Science 2023cited by 25position: middledoi
Constructing an individualized surveillance framework for nasopharyngeal carcinoma based on a dynamic risk-adapted approach
Radiotherapy and Oncology 2023cited by 13position: middledoi
Identification of immune-related genes contributing to head and neck squamous cell carcinoma development using weighted gene co-expression network analysis.
2023cited by 5position: contributordoi
Prioritizing sufficient dose to gross tumor volume over normal tissue sparing in intensity-modulated radiotherapy treatment of T4 nasopharyngeal carcinoma.
2023cited by 5position: contributordoi
Publisher Correction: Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial
Nature Medicine 2022cited by 3position: middledoi
Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial
Nature Medicine 2021cited by 399position: middledoi
Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III Study
Journal of Clinical Oncology 2021cited by 103position: middledoi
Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study)
Journal for ImmunoTherapy of Cancer 2021cited by 94position: middledoi
High Expression of Hyaluronan-Mediated Motility Receptor Predicts Adverse Outcomes: A Potential Therapeutic Target for Head and Neck Squamous Cell Carcinoma
Frontiers in Oncology 2021cited by 31position: middledoi
Modified reduced-volume intensity-modulated radiation therapy in non-metastatic nasopharyngeal carcinoma: A prospective observation series
Radiotherapy and Oncology 2021cited by 28position: middledoi
Level Ib sparing intensity-modulated radiation therapy in selected nasopharyngeal carcinoma patients based on the International Guideline
Radiotherapy and Oncology 2021cited by 21position: middledoi
Dose escalation and expansion (phase Ia/Ib) study of GLS-010, a recombinant fully human antiprogrammed death-1 monoclonal antibody for advanced solid tumors or lymphoma
European Journal of Cancer 2021cited by 18position: middledoi
SEC61G overexpression and DNA amplification correlates with prognosis and immune cell infiltration in head and neck squamous cell carcinoma.
2021cited by 16position: contributordoi
SEC61G overexpression and DNA amplification correlates with prognosis and immune cell infiltration in head and neck squamous cell carcinoma
Cancer Medicine 2021cited by 16position: middledoi
JUPITOR-02: Randomized, Double-Blind, Phase 3 Study of Toripalimab or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma
SSRN Electronic Journal 2021cited by 0position: middledoi
SEC61G Overexpression and DNA Amplification Correlates With Prognosis and Immune Cell Infiltration in Head and Neck Squamous Cell Carcinoma
2021cited by 0position: contributordoi
SEC61G Overexpression and DNA Amplification Correlates With Prognosis and Immune Cell Infiltration in Head and Neck Squamous Cell Carcinoma
2021cited by 0position: contributordoi
Circulating Epstein-Barr virus microRNAs BART7-3p and BART13-3p as novel biomarkers in nasopharyngeal carcinoma.
2020cited by 34position: contributordoi
Effects of oral maintenance chemotherapy and predictive value of circulating EBV DNA in metastatic nasopharyngeal carcinoma.
2020cited by 14position: contributordoi
High Soluble Programmed Death-Ligand 1 Predicts Poor Prognosis in Patients with Nasopharyngeal Carcinoma.
2020cited by 12position: contributordoi
Neoadjuvant dose-modified docetaxel in squamous cell carcinoma of the head and neck: A phase 3 study.
2020cited by 9position: contributordoi
Diagnostic and prognostic performance of circulating levels of the Epstein-Barr virus microRNAs BART 7-3p and BART 13-3p in nasopharyngeal carcinoma
2020cited by 0position: contributordoi
International Guideline on Dose Prioritization and Acceptance Criteria in Radiation Therapy Planning for Nasopharyngeal Carcinoma.
2019cited by 131position: contributordoi
Prognostic value of radiologic extranodal extension and its potential role in future N classification for nasopharyngeal carcinoma
Oral Oncology 2019cited by 62position: contributordoi
Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.
2019cited by 51position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 9 papers (2020–2023)Jianji Pan · Nanchang University8 papers (2019–2023) · 8 papers (2013–2025)Tianzhu Lu · Sun Yat-sen University Cancer Center7 papers (2021–2025) · 5 papers (2013–2023) · 5 papers (2016–2025) · 4 papers (2021–2025)Jingao Li · Jiangxi Provincial Cancer Hospital4 papers (2021–2023) · 3 papers (2016–2021)Shao Hui Huang · University of Toronto3 papers (2019–2019)Honglin Chen · Shanghai Institute of Technology3 papers (2019–2020)Qiaojuan Guo · Elsevier, Inc.3 papers (2019–2023) · 3 papers (2019–2019) · 3 papers (2021–2023)Yan Sun · Peking University2 papers (2019–2021)Shaojun Lin · Hainan Medical College Hospital2 papers (2013–2023)Libin Liu · Fujian Medical University2 papers (2023–2023)Da Zhang · Sun Yat-sen University Cancer Center2 papers (2023–2023)Lei Wang · Zhejiang Chinese Medical University2 papers (2023–2023)Xiaochang Gong · Nanchang University2 papers (2021–2021)
Looking for a research collaborator?
Search millions of scientists by field, institution, impact, and funding status — see their work, find their email, and reach out directly.
Find collaborators in Otorhinolaryngology · Surgery →